CTMXNasdaqPharmaceutical PreparationsUS GAAP · USD

CytomX Therapeutics, Inc.

CytomX Therapeutics is a clinical-stage biopharmaceutical company built around its PROBODY platform, which masks biologic drug activity until it reaches the tumor microenvironment. The company develops conditionally activated oncology candidates across modalities including T-cell engagers, antibody-drug conjugates, cytokines, immunotherapies, and mRNA, and it also partners its platform with large pharma companies to fund development and broaden reach.

Kysy yhtiöstä
Liikevaihto76,2milj. USD
−44,8 %v/v
Liikevoitto (EBIT)−22,4milj. USD
−189,5 %v/v
EBIT-marginaali−29,3%
−47,4 %-yks.v/v
Nettotulos−17,4milj. USD
−154,5 %v/v
Vapaa kassavirta−75,8milj. USD
+12,4 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−200−1000100200milj. USD2020: 68 milj. USD2020: EBIT −81 milj. USD20202021: 37 milj. USD2021: EBIT −116 milj. USD20212022: 53 milj. USD2022: EBIT −101 milj. USD20222023: 101 milj. USD2023: EBIT −6,5 milj. USD20232024: 138 milj. USD2024: EBIT 25 milj. USD20242025: 76 milj. USD2025: EBIT −22 milj. USD202576−22
LiikevaihtoLiikevoitto (EBIT)

Liiketoiminta

Osuus liikevaihdosta
PROBODY platform0 %

Masked biologic technology that conditionally activates therapeutic candidates in diseased tissue.

Partnered collaboration programs70 %

Research, license, and milestone-based programs with large biopharma partners.

Wholly owned oncology pipeline20 %

Internal drug candidates advanced by CytomX, including CX-2051 and preclinical assets.

Platform-enabled discovery services10 %

Collaborative R&D work that generates upfront, milestone, and reimbursement revenue.

Asiakkaat

CytomX's direct customers are not patients or hospitals; they are pharmaceutical and biotechnology partners that license the platform, fund research, and pay milestones as programs advance. The company also serves as a discovery and development collaborator for oncology-focused drug programs, especially in T-cell engagers, ADCs, cytokines, and mRNA. End-market demand is therefore driven by partner appetite for differentiated oncology assets and by the ability of CytomX's masking technology to improve therapeutic windows.

Large pharmaceutical partners

Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna fund and advance partnered programs through collaboration, milestone, and license structures.

Biotechnology collaborators

Smaller and mid-sized biotech firms use the PROBODY platform to access masked biologic design capabilities and oncology development support.

Internal oncology pipeline

CytomX itself is the end user of its platform for wholly owned programs such as CX-2051 and CX-908.

Future commercial oncology patients

If candidates are approved, cancer patients would be the eventual end market for the company's therapies.

Strategia

CytomX is prioritizing its most promising internal asset, CX-2051, while continuing to use partnerships to extend the PROBODY platform and conserve capital. Management has also restructured the organization to reduce costs and focus resources on programs with the highest strategic value, especially masked T-cell engager work and other partnered discovery efforts. The strategy is to maximize optionality: advance select wholly owned assets while using collaborations to generate non-dilutive funding and validation.

Focus capital on CX-2051Lyhyt aikaväli

Concentrating resources on the lead wholly owned program improves the chance of creating a value-driving clinical asset.

Expand partnered masked T-cell engager programsKeskipitkä aikaväli

Partnering lowers development cost while extending the platform into a high-interest oncology modality.

Broaden PROBODY across multiple modalitiesPitkä aikaväli

Applying masking technology to ADCs, cytokines, and mRNA increases the addressable pipeline and partnering opportunities.

Maantiede

CytomX is headquartered in the United States and operates as a U.S.-based clinical-stage biotech with research and collaboration activity centered around its domestic organization. Its business is global in partner reach, with collaborations involving multinational pharma companies, but the company does not disclose meaningful country-level revenue concentration in the provided excerpts. Because it has no approved products and no internal manufacturing footprint, geography mainly matters through partner locations, clinical trial execution, and third-party supply chains.

Riskit

CytomX faces the classic risks of a clinical-stage biotech: no approved products, recurring losses, and dependence on future financing and partner execution. Its platform also competes in crowded oncology categories where masking, ADC, and T-cell engager approaches are being pursued by large, well-capitalized companies, while development and regulatory outcomes remain uncertain. Because revenue is driven by collaboration timing and milestone events, results can be volatile quarter to quarter.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Lack of approved products and product revenue1Liquidity and financing risk2Partner concentration and program termination3Clinical and regulatory development risk4Competitive pressure in oncology platforms5
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Lack of approved products and product revenueVaikutus: KorkeaTodennäköisyys: Korkea

    The company is still clinical-stage, so it depends on collaboration revenue and future approvals that may never occur.

    Kohdistuu: All programs

  2. Liquidity and financing riskVaikutus: KorkeaTodennäköisyys: Korkea

    Operating losses and R&D spending require external capital; management said existing resources fund operations only into Q2 2026.

    Kohdistuu: Corporate

  3. Partner concentration and program terminationVaikutus: KorkeaTodennäköisyys: Korkea

    Revenue and development progress depend on a small number of collaboration partners and their budget priorities.

    KohdistuuAmgenAstellasBMSRegeneronModerna
  4. Clinical and regulatory development riskVaikutus: KorkeaTodennäköisyys: Korkea

    Preclinical and clinical candidates may fail to show efficacy, safety, or manufacturability required for approval.

    KohdistuuCX-2051CX-904CX-908CX-801
  5. Competitive pressure in oncology platformsVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Large pharma and biotech peers are developing competing ADC, TCE, masking, and immuno-oncology products.

    Kohdistuu: PROBODY platform and pipeline

Kirjanpito

Harkinnanvaraiset erät
Over-time collaboration revenue recognition

Revenue depends on estimated performance obligations and FTE hours, so changes in estimates can shift timing materially.

Vaikutus: Affects reported revenue and quarterly comparability

Variable consideration and milestones

Milestone revenue is recognized only when probable and not subject to significant reversal, making timing judgmental.

Vaikutus: Can create lumpy revenue from partner achievements

Restructuring charges

The 2025 restructuring plan likely creates severance and related costs that affect operating expenses and cash usage.

Vaikutus: Impacts near-term margins and liquidity

Tax valuation allowances and NOLs

Persistent losses and accumulated deficit make realization of deferred tax assets uncertain.

Vaikutus: Can affect effective tax rate and balance sheet presentation

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

CytoDyn Inc.

CYDY · Pharmaceutical Preparations

Compass Therapeutics, Inc.

CMPX · Biological Products, (No Diagnostic Substances)

Marker Therapeutics, Inc.

MRKR · Pharmaceutical Preparations

Janux Therapeutics, Inc.

JANX · Pharmaceutical Preparations

Xilio Therapeutics, Inc.

XLO · Pharmaceutical Preparations

XBiotech Inc.

XBIT · Pharmaceutical Preparations

Päivitetty: 24.9.2026